{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:03:34Z","timestamp":1786118614881,"version":"build-2736575974"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Clinical Psychopharmacology"],"published-print":{"date-parts":[[1996,3]]},"DOI":"10.1097\/00004850-199603000-00007","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T04:48:52Z","timestamp":1165985332000},"page":"53-54","source":"Crossref","is-referenced-by-count":17,"title":["Risperidone appears safe in patients with antipsychotic-induced blood dyscrasias"],"prefix":"10.1097","volume":"11","author":[{"given":"T.","family":"Mahmood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Silverstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Spittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["International Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004850-199603000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:16:34Z","timestamp":1786032994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004850-199603000-00007"}},"subtitle":[""],"short-title":[],"issued":{"date-parts":[[1996,3]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1097\/00004850-199603000-00007","relation":{},"ISSN":["0268-1315"],"issn-type":[{"value":"0268-1315","type":"print"}],"subject":[],"published":{"date-parts":[[1996,3]]}}}